Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-Claudin18.2 CAR T cells IM92

A preparation of T lymphocytes engineered to express a chimeric antigen receptor (CAR) specific for the tumor-associated antigen (TAA) Claudin18.2 (CLDN18.2; A2 isoform of claudin-18), with potential immunostimulating and antineoplastic activities. Upon administration, anti-CLDN18.2 CAR T cells IM92 specifically recognize and induce selective toxicity in CLDN18.2-expressing tumor cells. CLDN18.2, a tight junction protein, is expressed on a variety of tumor cells, but its expression in healthy tissues is strictly confined to short-lived differentiated epithelial cells of the gastric mucosa.

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Synonym:	anti-CLDN18.2 CAR T cells IM92
Code name:	IM 92 IM-92 IM92

anti-Claudin18.2 CAR T cells IM92

Search NCI's Drug Dictionary